Early and late treatment failure in community-acquired pneumonia

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 2, 2009, Pages 154-160

  Garcia Vidal, Carolina ^a   Carratalà, Jordi ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Biomarkers; Community acquired pneumonia; Early failure; Inflammatory response; Late failure

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; GRAM NEGATIVE INFECTION; HIGH RISK PATIENT; HOSPITAL PATIENT; HOST PATHOGEN INTERACTION; HUMAN; INCIDENCE; INFLUENZA VACCINATION; LEGIONELLA; LEUKOPENIA; LIVER DISEASE; LUNG CAVITATION; MORBIDITY; MORTALITY; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; EVIDENCE-BASED MEDICINE; HOSPITALIZATION; HUMANS; INCIDENCE; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SPAIN; TREATMENT FAILURE;

EID: 63149128595     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1202934     Document Type: Review

References (37)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72
2. Menéndez R, Torres A. Treatment failure in community-acquired pneumonia. Chest 2007;132:1348-1355
3. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-160
4. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-508
5. Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-965
6. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-452
7. Hoogewerf M, Oosterheert JJ, Hak E, Hoepelman IM, Bonten MJM. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 2006;12:1097-1104
8. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993;147:38-44
9. Örtqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990;97:576-582
10. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomized trial. BMJ 2006;333:1193-1197
11. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-1011
12. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-631
13. Davidson R, Cavalcante R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-750
14. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 2004;38(Suppl 4):S357-S362
15. Garcia-Vidal C, Fernández-Sabé N, Carratalà J, et al. Early mortality in patients with community-acquired pneumonia: causes, and risk factors. Eur Respir J 2008;32:733-739
16. Monton C, Torres A, El-Ebiary M, et al. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999;27:1745-1753
17. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-248
18. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007;30:951-956
19. Sibila O, Agustí C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J 2008;32:259-264
20. Carratalà J, Martín-Herrero JE, Mykietiuk A, García-Rey C. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clin Microbiol Infect 2006;12(Suppl 3):2-11
21. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-755
22. Carratalà J, Fernández-Sabé N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005;142:165-172
23. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-1972
24. Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P, Moxirapid Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697-1705
25. Mykietiuk A, Carratalà J, Fernández-Sabé N, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005;40:794-799
26. Dalhoff A, Shalit I. Immunomodulatory effect of quinolones. Lancet Infect Dis 2003;3:359-371
27. Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008;52:2395-2402
28. Gross PA, Hermogenes AW, Sacks HS, et al. the efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527
29. Spaude KA, Brutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007;167:53-59
30. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001;119(Suppl 2):419S-425S
31. Skerrett SJ, Park DR. Anti-inflammatory treatment of acute and chronic pneumonia. Semin Respir Infect 2001;16:76-84
32. Fernández-Serrano S, Dorca J, Coromines M, Carratalà J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003;10:813-820
33. Póvoa P. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 2008;21:157-162
34. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein: a clinical marker in community-acquired pneumonia. Chest 1995;108:1288-1291
35. Coelho L, Póvoa P, Almeida E, et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11:R92
36. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-225
37. Bruns AHW, Oosterheert JJ, Hak E, Hoepelman AIM. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008;32:726-732